Ambrisentan/tadalafil - GlaxoSmithKline

Drug Profile

Ambrisentan/tadalafil - GlaxoSmithKline

Alternative Names: Tadalafil/ambrisentan

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Hammersmith Medicines Research
  • Class Antihypertensives; Benzodioxoles; Carbolines; Indoles; Phenylpropionates; Pyridazines; Small molecules
  • Mechanism of Action Endothelin A receptor antagonists; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pulmonary hypertension

Most Recent Events

  • 04 Aug 2017 GlaxoSmithKline completes a phase I trial in Pulmonary hypertension (In volunteers) in United Kingdom (PO) (NCT02688387)
  • 01 Mar 2016 Phase-I clinical trials in Pulmonary hypertension (In volunteers) in United Kingdom (PO) (NCT02688387)
  • 18 Feb 2016 GlaxoSmithKline plans a phase I pharmacokinetics trial in Healthy volunteers in United Kingdom (PO) (NCT02688387)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top